Recent patents on treatment of severe acute respiratory syndrome (SARS).
Severe acute respiratory syndrome (SARS) is an epidemic that spread worldwide in early 2003. The aetiological agent was originally defined as a novel coronavirus and later designated as the SARS coronavirus (SARS-CoV), which appears similar to other coronaviruses in both virion structure and genome organization with a single-stranded, plus-sense RNA. However, the epidemiology and pathogenesis of SARS remain poorly understood and there is currently no effective treatment. To date, considerable research has been done on detection, prevention and treatment of SARS. In this review, we mainly focus on the recent patents and research work on detecting, preventing and treating SARS.
Zhai
Shumei
S
School of Pharmaceutical Sciences and Institute of Environmental Sciences, Shandong University, Jinan, Shandong, China.
Liu
Wei
W
Yan
Bing
B
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D000086782:Coronavirus 3C Proteases; D003546:Cysteine Endopeptidases; D006801:Humans; D010330:Patents as Topic; D011480:Protease Inhibitors / Q000627:therapeutic use; D034741:RNA, Small Interfering / Q000494:pharmacology / Q000627:therapeutic use; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects / Q000235:genetics; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy* / Q000517:prevention & control / Q000821:virology; D014764:Viral Proteins / Q000037:antagonists & inhibitors; D014765:Viral Vaccines / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D011480:Protease Inhibitors; D034741:RNA, Small Interfering; D014764:Viral Proteins; D014765:Viral Vaccines; D003546:Cysteine Endopeptidases; D000086782:Coronavirus 3C Proteases